Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Trintellix (vortioxetine) is indicated for the treatment of major depressive disorder (MDD) in adults.
• This summary is based on the review of 23 systematic review(s)/meta-analysis(es). ^[1-23]
• Response Rate, Remission Rate, and Symptom Improvement: Vortioxetine significantly improved response and remission rates compared to placebo, with notable improvements in depression symptoms, cognitive function, and functional disability, as measured by MADRS, HADRS-24, SDS, and CGI-I total scores.
• Cognitive Function: Vortioxetine showed superior efficacy in improving cognitive function, as evidenced by better scores on DSST, PDQ, and MADRS, compared to other antidepressants.
• Comparison with Other Antidepressants: Vortioxetine was better tolerated than SNRIs but showed no significant differences in response or remission rates when compared with SSRIs and SNRIs. Probiotics were found to be more effective than vortioxetine in treating MDD.
• Specific Dosage Effectiveness: Both 10 mg and 20 mg doses of vortioxetine were effective in improving depression symptoms, with consistent outcomes across various studies.
• Adverse Events: Nausea was the most commonly reported adverse event associated with vortioxetine, with hyperhidrosis, insomnia, and vomiting also frequently reported, especially at higher doses. Additionally, vortioxetine had a reduced risk of insomnia, somnolence, and blurred vision compared to other second-generation antidepressants.
• Discontinuation Rates: Vortioxetine had higher discontinuation rates due to adverse events compared to placebo and demonstrated better tolerability compared to SNRIs, while being similar to SSRIs in this regard.
• Significant Safety Concerns in Specific Populations: Older adults treated with vortioxetine exhibited a higher incidence of at least one adverse event. In patients with high frailty, mild-to-moderate nausea was the most frequently reported issue.
• There is no population types or subgroups information available in the reviewed studies.